Biohaven Pharmaceuticals Annual Revenue, Number of Employees, Growth and Funding

Claim your profile


New Haven, CT USA
Total Funding:$248.3M
Lead Investor(s):Goldman Sachs & Co. LLC, Piper Jaffray & Co.
Claim your profile

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Biohaven Pharmaceuticals's estimated annual revenue is currently $26M per year.
  • Biohaven Pharmaceuticals received $143.7M in venture funding in December 2018.
  • Biohaven Pharmaceuticals's estimated revenue per employee is $144,667
  • Biohaven Pharmaceuticals's total funding is $248.3M.

Employee Data

  • Biohaven Pharmaceuticals has 180 Employees.
  • Biohaven Pharmaceuticals grew their employee count by 195% last year.
  • Biohaven Pharmaceuticals currently has 34 job openings.

Executive Contacts

Gene DubowchikVP Chemistry, Research and Development
Mark GlackinVice President, Migraine Sales & Marketing
Robert CroopChief Development Officer - Neurology
Francine HealyExecutive Director
Ashwini GhatpandeVice President, Scientific Writing and Regulatory Submissions
Marianne FrostExecutive Director
Andrea IvansDirector, Clinical Operations
Victoria WirtzSr Director, Biostatistics
Clifford BechtoldChief Operating Officer
David LoomisVP & Corporate Controller

Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. Biohaven obtained licenses from Yale University School of Medicine and Massachusetts General Hospital regarding intellectual property relating to the use of certain glutamate modulating agents in the treatment of neuropsychiatric disorders. The mission of the company is to exploit advances over the past decade in the understanding of glutamate mechanisms involved in a variety of diseases. The company's first drug candidate is being developed for orphan neurological disorders as well as treatment-resistant anxiety and depression. Biohaven has assembled a team of experts who have extensive experience in the development of therapeutic agents in this area and also comprise the originators at Yale University who discovered the therapeutic potential of glutamate modulation in anxiety and depression. Team members have designed and executed successful development programs testing a variety of agents in affective disorders, leading to first-cycle FDA approvals and successful commercialization.



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Metrum Research...
Biological Indu...
Biohaven Pharma...

Biohaven Pharmaceuticals News

08/09/2019 - Biohaven Pharmaceuticals Reports Second Quarter 2019 ...

Submitted Two New Drug Applications (NDAs) to FDA for Zydis® Orally Dissolving Tablet (ODT) and tablet formulations of rimegepant in the ...

08/09/2019 - Spotting Wide-Moat Stocks: Biohaven Pharmaceutical Holding ...

The recent performance of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) stock in the market spoke loud and clear to ...

09/04/2019 - Biohaven up 7% on accelerated rimegepant timeline

Biohaven Pharmaceutical Holding Company (BHVN +7.3%) is up, albeit on light volume, in reaction its corporate update that includes an ...

Biohaven Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2018-06-20$150.0MUndisclosedRoyalty PharmaArticle
2018-12-13$143.7MUndisclosedGoldman Sachs & Co. LLCArticle

Biohaven Pharmaceuticals Executive Hires

2017-06-23Elyse StockChief of Portfolio Strategy and DevelopmentArticle
2017-10-26Clifford BechtoldChief Operating OfficerArticle
2017-11-13Scott PhillipsSVP FinanceArticle